Ameriprise
MIRM icon

Ameriprise’s Mirum Pharmaceuticals MIRM Stock Holding History

Ameriprise’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.1M Buy
726,694
+507,439
+231% +$50.9M 0.02% 674
2026
Q1 		$20.3M Sell
219,255
-52,225
-19% -$4.91M ﹤0.01% 1400
2025
Q4 		$21.4M Buy
271,480
+68,412
+34% +$4.91M ﹤0.01% 1365
2025
Q3 		$14.9M Sell
203,068
-39,692
-16% -$2.52M ﹤0.01% 1612
2025
Q2 		$12.4M Buy
242,760
+46,877
+24% +$2.09M ﹤0.01% 1662
2025
Q1 		$8.82M Buy
195,883
+1,807
+0.9% +$85.2K ﹤0.01% 1853
2024
Q4 		$8.02M Buy
194,076
+10,732
+6% +$447K ﹤0.01% 1981
2024
Q3 		$7.15M Buy
183,344
+168,037
+1,098% +$6.7M ﹤0.01% 2107
2024
Q2 		$523K Sell
15,307
-3,720
-20% -$97.5K ﹤0.01% 3401
2024
Q1 		$478K Sell
19,027
-11,550
-38% -$318K ﹤0.01% 3434
2023
Q4 		$903K Buy
30,577
+180
+0.6% +$5.45K ﹤0.01% 3225
2023
Q3 		$961K Buy
30,397
+13,314
+78% +$365K ﹤0.01% 3159
2023
Q2 		$442K Sell
17,083
-1,882
-10% -$50.1K ﹤0.01% 3487
2023
Q1 		$456K Buy
+18,965
New +$432K ﹤0.01% 3466

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's MIRM Position: Q2 2026 in Review

Ameriprise increased its Mirum Pharmaceuticals (MIRM) stake by 231% in Q2 2026, buying an estimated $50.9M and bringing the position to 726,694 shares worth $85.1M. The position accounts for 0.02% of the portfolio, ranked #674.

Ameriprise first reported a position in MIRM in Q1 2023 and has held it in 14 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Ameriprise held 726,694 shares of Mirum Pharmaceuticals worth $85.1M as of Q2 2026.
  • Ameriprise bought 507,439 Mirum Pharmaceuticals shares in Q2 2026, an estimated $50.9M.
  • Mirum Pharmaceuticals made up 0.02% of Ameriprise's portfolio in Q2 2026, its #674 holding.
  • Ameriprise first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.